Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Evolution of Gilteritinib Resistance from Residual Disease to Relapse

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139084

Published: 2020

Journal Articles

Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models

Elana Thieme, Vi Lam, Nur Bruss, BS, Fei Xu, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Alexey Danilov, MD, Tingting Liu

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-134957

Published: 2020

Journal Articles

Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Tingting Liu, Fei Xu, Elana Thieme, Vi Lam, Guang Fan, MD PhD, Liana Nikolaenko, MD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Olga Danilova, Alexey Danilov, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-134951

Published: 2020

Journal Articles

Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia

James T Dibb, DO, Nicola Long, Christopher A. Eide, Stephen E Kurtz, PhD, Cristina E. Tognon, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-137674

Published: 2020

Journal Articles

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Rucha V Modak, PhD, Sara J Gosline, Alisa Damnernsawad, PhD, Tamilla Nechiporuk, PhD, Ted Laderas, PhD, Guanming Wu, PhD, Paul Piehowski, Paul.Piehowski@pnnl.gov, Stephen E Kurtz, PhD, Christopher A. Eide, Jeffrey W. Tyner, PhD, Karin Rodland, rodland@ohsu.edu, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141686

Published: 2020

Journal Articles

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Anna Reister Schultz, BS, Thomas Jacob, Christopher A. Eide, Samantha L Savage, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Tania Q. Vu, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2018-99-115387

Published: 2018

Journal Articles

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Stephen E Kurtz, PhD, Cristina E. Tognon, PhD, Leylah M. Drusbosky, PhD, Robinson Vidva, B.Tech, Yugandhara Narvekar, M.Sc., Ashish Kumar Agrawal, B.V.Sc, A.H., Saji Gera, M.Tech, Samiksha Avinash Prasad, M.Sc., Vijayashree P Shyamasundar, M.Sc., Gaurav Singh Tunwer, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2018-99-115284

Published: 2018

Journal Articles

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Leylah M. Drusbosky, PhD, Diwyanshu Sahu, M.Sc., Robinson Vidva, B.Tech, Shweta Kapoor, M.Sc., Humera Azam, M.Sc., Rajeev Kumar, B.Tech, Padmagiri G Chickdipatti, B.E, Nithya T Raveendaran, M.Tech, Reshma P Gopi, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2018-99-115678

Published: 2018

Journal Articles

Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia

Jessica Leonard, MD, Yoko Kosaka, PhD, Matthew T Newman, BS, Adam J. Lamble, MD, Pavani Malla, MS, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Bill H. Chang, MD PhD, Evan F. Lind, PhD

Blood (2018) 132 (Supplement 1): 1547.

https://doi.org/10.1182/blood-2018-99-119409

Published: 2018

Journal Articles

Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

Haijiao Zhang, Beth Wilmot, PhD, Daniel Bottomly, Stephen E Kurtz, PhD, Christopher A. Eide, Alisa Damnernsawad, Kyle Romine, Shyam Patel, Brian J. Druker, MD, Schannon K Mcweeney, Ravi Majeti, MD PhD, Jeffrey W. Tyner, PhD

Blood (2018) 132 (Supplement 1): 175.

https://doi.org/10.1182/blood-2018-175

Published: 2018

Journal Articles

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Bill H. Chang, MD PhD, Jessica Leonard, MD, Joelle Wolf, Michelle Degnin, BS, Kyle Lenz, MD, Beth Wilmot, PhD, Charles G. Mullighan, MBBS, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2018-99-115706

Published: 2018

Journal Articles

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Kim-Hien Dao, DO,PhD, Robert H. Collins, MD, Jorge E. Cortes, MD, Michael W. Deininger, MD PhD, Brian J. Druker, MD, Jason R. Gotlib, MDMS, Tara Alyson Macey, PhD, Stephen T Oh, MD PhD, Jeffrey W. Tyner, PhD, Elliott F. Winton, MD

Blood (2018) 132 (Supplement 1): 350.

https://doi.org/10.1182/blood-2018-99-119476

Published: 2018

Journal Articles

CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Hongying Zhang, MD, PhD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Taryn McLaughlin, MS, Alexey V Danilov, MD PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Stephen Howell, MD, William G Rice, PhD

Blood (2018) 132 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2018-99-117285

Published: 2018

Journal Articles

The 3-Drug Combination Treatment ART838, ABT199 Plus Sorafenib Is Effective Against AML Xenografts, Possibly Via Cooperative Targeting of MCL1

Blake S Moses, PhD, Jennifer Fox, PhD, Xiaochun Chen, PhD, Samantha McCullough, BS, Sang Ngoc Tran, BA, Allison Kirkpatrick, BS, Kalyani Kumar, BS, Jeffrey W. Tyner, PhD, Gary H. Posner, PhD, Curt I. Civin, MD

Blood (2018) 132 (Supplement 1): 4044.

https://doi.org/10.1182/blood-2018-99-113040

Published: 2018

Journal Articles

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Blood (2018) 132 (Supplement 1): 261.

https://doi.org/10.1182/blood-2018-99-116948

Published: 2018

Journal Articles

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

Lauren K. Brady, PhD, David Soong, PhD, Evan F. Lind, PhD, Yoko Kosaka, PhD, Adam J. Lamble, MD, Michael Schaffer, PhD, Brendan P. Hodkinson, PhD, Clare Lefave, PhD, Ted Laderas, PhD, Shannon K. McWeeney, PhD, Homer Adams, III, PhD, Yann Abraham, PhD, Pegah Safabakhsh, MS, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Fei Huang, PhD

Blood (2018) 132 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2018-99-118424

Published: 2018

Journal Articles

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Brian S. White, PhD, Suleiman A. Khan, PhD, Muhammad Ammad-ud-din, PhD, Swapnil Potdar, MSc, Mike J Mason, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD, Caroline A Heckman, PhD, Olli Kallioniemi, MD PhD, Stephen E Kurtz, PhD, Kimmo Porkka, MD PhD, Jeffrey W. Tyner, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Justin Guinney, PhD

Blood (2018) 132 (Supplement 1): 2763.

https://doi.org/10.1182/blood-2018-99-111916

Published: 2018

Journal Articles

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Stephen E Kurtz, PhD, Christopher A. Eide, Narain P. Dubey, Andy Kaempf, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Anupriya Agarwal, PhD

Blood (2018) 132 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2018-99-117537

Published: 2018

Journal Articles

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Jessica Leonard, MD, Yoko Kosaka, PhD, Pavani Malla, MS, Brandon Hayes-Lattin, MD, Adam J. Lamble, MD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Bill H. Chang, MD PhD, Evan F. Lind, PhD

Blood (2018) 132 (Supplement 1): 2694.

https://doi.org/10.1182/blood-2018-99-119301

Published: 2018

Journal Articles

Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, Cristina E. Tognon, PhD, Motomi Mori, PhD, Max J. Gordon, MD, Jeffrey W. Tyner, PhD, Alexey V Danilov, MD PhD, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 214.

https://doi.org/10.1182/blood-2018-99-117468

Published: 2018

NARROW

Evolution of Gilteritinib Resistance from Residual Disease to Relapse

Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models

Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia

Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

The 3-Drug Combination Treatment ART838, ABT199 Plus Sorafenib Is Effective Against AML Xenografts, Possibly Via Cooperative Targeting of MCL1

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only